Porsolt is a global CRO based in France.We provide a broad range of contract services for non-clinical development, ranging from early drug discovery screening to pharmacology, safety evaluation, pharmacokinetics, and support toward regulatory submissions.The tests are conducted not by an agency, but by our own research facility and specialized staff.
In Porsolt,Central nervous system, cardiovascular, inflammation, oncology, pain, respiratory, liver disease, metabolic disease, skin disease, etc.We support non-clinical research across a wide range of fields. Equipped with various evaluation systems including in vitro, ex vivo, in ovo, and in vivo, we conduct pharmacological studies using multiple animal species. We can develop testing systems tailored to your research objectives, ranging from early-stage drug discovery screening to the efficacy evaluation of candidate compounds.
In the safety evaluation,Pharmacological and toxicological tests compliant with GLPare being conducted. We support studies evaluating effects on the cardiovascular, central nervous, and respiratory systems as a core battery based on ICH S7. A wide range of evaluations from in vitro to in vivo is possible, including hERG channel assays, blood pressure, heart rate, and electrocardiogram measurements, as well as respiratory function evaluations. Porsolt has continuously maintained its GLP compliance status since passing a GLP compliance audit in 2000.
Not only efficacy evaluation,pharmacokinetic study, formulation analysis, bioanalysis, toxicity evaluationWe also offer services such as pharmacokinetics using multiple animal species including mice, rats, dogs, and minipigs, with the capability to collect samples of blood, plasma, cerebrospinal fluid, and various tissues. In addition, we provide scientific support for regulatory submissions at each stage of non-clinical development.
At Porsolt, we have developed various in vivo and in vitro models for each disease area. For example, in the oncology field,orthotopic and subcutaneous xenograft models targeting breast cancer, lung cancer, colorectal cancer, glioblastoma, etc.Supports drug efficacy evaluation using [X]. Models can be selected according to the disease and evaluation purpose.
The Porsolt official website publishes papers and research results related to non-clinical research. For example,A study continuously evaluating drug withdrawal in rats using telemetryNow, we are measuring body temperature, amount of exercise, heart rate, mean arterial pressure, and other parameters over time. On the other hand, case studies summarizing the contents and results of trials commissioned by individual pharmaceutical companies are limited on our official website.
| Address | Z.A. de Glatigné, 53940 Le Genest-Saint-Isle, France |
|---|---|
| Tel | +33 2 43 69 36 07 |
| Website | https://www.porsolt.com/ |
In non-clinical development, the choice of contract research organization shapes the quality of the data and the time it takes to reach the next decision. Below, three CROs are introduced by the type of study they support: pharmacology (efficacy) studies, safety studies, and pharmacokinetic (PK/PD) studies. Each summary describes the services the company offers so that you can match a provider to your target and development objective.
SMC Laboratories is a specialized non-clinical CRO focused on in vivo pharmacology and efficacy studies using disease-relevant animal models, particularly in fibrosis, inflammation, metabolic diseases, and oncology.
SMC Laboratories offers models covering the liver, lung, kidney, intestine, and oncology. Its portfolio includes the proprietary STAM™ model for MASH, fibrosis, and hepatocellular carcinoma.
Study plans are developed around the target biology, mechanism of action, disease stage, and development objective. Pharmacological endpoints can be combined with histopathology, biomarkers, and disease-specific readouts.
With experience from more than 1,000 studies for clients in 30 countries, SMC Laboratories supports programs from target validation and candidate selection through in vivo proof-of-concept studies.
Charles River provides non-clinical toxicology and safety assessment services for programs ranging from exploratory safety studies to IND-enabling development.
Services include single- and repeat-dose toxicology, dose-range finding, and general toxicology studies across multiple species and administration routes.
Charles River supports both non-GLP and GLP studies, allowing sponsors to progress from early safety characterization to studies intended for regulatory submissions.
Toxicology studies can be integrated with toxicokinetics, clinical pathology, histopathology, and safety pharmacology to support interpretation and IND-enabling safety packages.
Inotiv provides integrated PK/PD, DMPK, and bioanalytical services to characterize drug exposure and its relationship with pharmacological response.
PK studies characterize exposure, half-life, clearance, and other pharmacokinetic parameters needed to understand how a candidate behaves in the selected model.
Pharmacokinetic data can be combined with pharmacodynamic endpoints and bioanalysis to evaluate the relationship between drug exposure and pharmacological response.
Integrated DMPK, pharmacology, and safety information supports candidate comparison, dose selection, dosing-frequency optimization, and decisions about subsequent preclinical development.